Epidemiological and laboratory animal model studies have suggested that nonsteroidal anti-
inflammatory drugs reduce the risk of development of colon cancer. The present study was …

Epidemiological and model studies with laboratory animals have provided evidence that
nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer. Sulindac, a …

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as sulindac, have cancer
chemopreventive properties by a mechanism that has been suggested to involve …

Several lines of evidence suggest that nonsteroidal antiinflammatory drugs may be effective
in preventing colorectal cancer. These include animal experiments, case-control studies …

Sulindac, a non‐steroidal anti‐inflammatory drug, has been reported to lead to tumour
regression in cases of human polyposis coli. We have investigated the effects of this drug on …

Epidemiological and laboratory studies indicate an inverse relationship between the risk of
colon cancer development and intake of nonsteroidal antiinflammatory agents, including …

• Sulindac (cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl) benzylidene] indene-3-acetic acid), an
inhibitor of prostaglandin synthesis, has been reported to cause regression of colon polyps …

Epidemiologic studies suggest that sustained use of aspirin may reduce the risk of
development of and mortality due to colon cancer. Previous preclinical studies have shown …

Colorectal cancer is the second leading cause of cancer death in the USA Recent research
suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in the prevention …

Nonsteroidal anti-inflammatory drugs such as sulindac have shown promising antineoplastic
activity, although toxicity from cyclooxygenase (COX) inhibition and the suppression of …